TSBX (Turnstone Biologics) Other Stockholders Equity : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Turnstone Biologics Other Stockholders Equity?

Turnstone Biologics's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $0.00 Mil.

Turnstone Biologics's quarterly Other Stockholders Equity declined from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($-0.00 Mil) but then increased from Jun. 2024 ($-0.00 Mil) to Sep. 2024 ($0.00 Mil).

Turnstone Biologics's annual Other Stockholders Equity declined from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) and declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Turnstone Biologics Other Stockholders Equity Historical Data

The historical data trend for Turnstone Biologics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turnstone Biologics Other Stockholders Equity Chart

Turnstone Biologics Annual Data

Trend

Dec21

Dec22

Dec23

Other Stockholders Equity

Turnstone Biologics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Stockholders Equity	Get a 7-Day Free Trial							-	-	-	-	-

Turnstone Biologics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Turnstone Biologics Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Turnstone Biologics's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Turnstone Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turnstone Biologics Corp (NAS:TSBX) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

9310 Athena Circle, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.turnstonebio.com

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Executives

Davis Jerel	director, 10 percent owner	ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Ventures V, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Robert J Gould	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Sammy J. Farah	director, officer: President & CEO	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Saryah Azmat	officer: Chief Business Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Venkat Ramanan	officer: Chief Financial Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Campisi Peter Joseph Jr.	officer: Chief Legal Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Vijay Chiruvolu	officer: Int. Chief Technology Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037
Versant Vantage Ii Gp, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kanya Rajangam	director	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Versant Ventures V Gp-gp (canada), Inc.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Michael F. Burgess	director, officer: Interim Chief Medical Officer	C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stewart Abbot	officer: Chief Scientific Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037